Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: June 15, 2016

Drug Name

Review Type

Class

Manufacturer
Dyanavel XR Susp.
New Drug Initial Review
Stimulants
Tris Pharma, Inc.
Viberzi
New Drug Initial Review
Irritable Bowel with diarrhea
Allergan
Xeljanz
New Drug Appeal
Rheumatoid Arthritis
Pfizer
Xeljanz XR
New Drug Appeal
Rheumatoid Arthritis
Pfizer
Savaysa
New Drug Appeal
NOAC Anti-Coagulant
Daiichi Sankyo
Orenitram
New Drug Appeal
Pulmonary Arterial Hypertension
United Therapeutics
Brilinta
PDL Appeal
Platelet Aggregation Inhibitor
AstraZeneca